Synapse - Andrew Seidman

Results (99)

Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer

Meeting Abstract

Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Meeting Abstract

Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
Cancer Research (2009)

Fulltext@MSK | Save

Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)

Meeting Abstract

Sierecki, M. R.; Rugo, H. S.; McArthur, H. L.; Traina, T. A.; Paulson, M.; Rourke, M.; Norton, L.; Seidman, A. D.; Hudis, C. A.; Dickler, M. N.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)

Meeting Abstract

Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and Leukemia Group B

Journal Article

Polite, B. N.; Cirrincione, C.; Fleming, G. F.; Berry, D. A.; Seidman, A.; Muss, H.; Norton, L.; Shapiro, C.; Bakri, K.; Marcom, K.; more...
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840

Journal Article

Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Muss, H.; Marcom, P. K.; Gipson, G.; Burstein, H.; Lake, D.; Shapiro, C. L.; more...
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

Journal Article

Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
Clinical Cancer Research (2008)

Fulltext@MSK | Save

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer